野生型JC病毒与芦可替尼治疗相关的致命性脑病
本文报告首例在接受含芦可替尼免疫抑制治疗后发生致命性JC病毒脑病的病例。尸检分析采用下一代测序、Sanger测序、组织免疫组化和7T磁共振成像,发现一株具有12bp插入的野生型JC病毒,抗VP1染色显示皮层神经元、海马神经元及胶质和内皮细胞感染。
要点
- 接受含芦可替尼免疫抑制治疗后可发生致命性JC病毒脑病。
- 分离的JC病毒为野生型背景下的12bp插入变异株。
- 病毒累及皮层神经元、海马神经元及胶质和内皮细胞。
核心结论
- 本研究扩展了与广谱免疫抑制(包括JAK-STAT抑制剂)相关的JC病毒疾病谱。
- 提示存在一种原型株背景的额外嗜神经病毒株。
研究设计与样本
- 首例接受含芦可替尼免疫抑制治疗后发生致命性JC病毒脑病的病例报告。
- 尸检分析包括下一代测序、Sanger测序、组织免疫组化和固定半球7T磁共振成像。
主要发现
- 从尸检组织样本分离的JC病毒DNA鉴定出新的12bp插入,改变了转录位点结合模式,其余为野生型病毒。
- 抗VP1染色显示皮层神经元、海马神经元以及胶质和内皮细胞存在感染。
临床怎么用
- 对接受JAK-STAT抑制剂等广谱免疫抑制治疗的患者,需警惕JC病毒脑病可能。
- JC病毒脑病的诊断可结合脑组织病理、免疫组化及分子检测。
局限性
- 本文为单例病例报告,结论的普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: JC virus (JCV) infection is a lytic infection of oligodendrocytes in progressive multifocal leukoencephalopathy; less common forms of central nervous system manifestations associated with JCV infection include granule cell neuronopathy, encephalopathy, and meningitis. Presented is the first case of fatal JCV encephalopathy after immunosuppressive therapy that included ruxolitinib. METHODS: Postmortem analysis included next generation sequencing, Sanger sequencing, tissue immunohistochemistry, and formalin-fixed hemisphere 7T magnetic resonance imaging. RESULTS: JCV DNA isolated from postmortem tissue samples identified a novel 12bp insertion that altered the transcription site binding pattern in an otherwise "wild-type virus," which has long been thought to be the nonpathogenic form of JCV. Anti-VP1 staining demonstrated infection in cortical neurons, hippocampal neurons, and glial and endothelial cells. INTERPRETATION: This expands the spectrum of identified JCV diseases associated with broad-spectrum immunosuppression, including JAK-STAT inhibitors, and sheds light on an additional neurotropic virus strain of the archetype variety. ANN NEUROL 2019;86:878-884.
引用
- Reoma LB, Trindade CJ, Monaco MC, et al. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol. 2019. PMID: 31600832. doi:10.1002/ana.25608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。